SAN FRANCISCO, California (April 29, 2025) — Grove AI, a company advancing the next generation of clinical trials with artificial intelligence, today announced that its AI Digital Staff™ agent, Grace, has received generic Institutional Review Board (IRB) approval for usage in participant recruitment and engagement workflows across clinical trials. This marks the central IRB’s first generic approval of an agentic AI platform designed specifically for clinical research. With this milestone, sites and sponsors can reference the use of Grace via an identification number in their study-specific material submissions without needing to include additional technical descriptions of the AI.

Grove AI worked closely with the central IRB to ensure a comprehensive understanding of Grace’s capabilities, compliance guardrails, and proprietary quality assurance systems that safeguard participant privacy and experience. This approval accelerates IRB submissions for research teams and maintains the rigorous ethical standards that clinical trials require. Grove is working with additional IRBs to expand this streamlined approval path for more studies and sponsors

Over the last year, Grace has prescreened and matched participants to trials with precision—handling over 480,000 calls, texts, and emails that resulted in over 12,000 in-person scheduled site visits across Phase I–III trials. By helping research teams prescreen and match participants to appropriate studies quickly and compliantly, Grove AI is accelerating clinical development timelines and expanding access to research.

The company will be at the 2025 STAT Breakthrough Summit West in San Francisco on May 14, 2025, to engage in discussions about the impact of AI and emerging tech on health innovation.